Empagliflozin in Patients With Glomerulonephritis

Status Completed

Clinical Trial Summary

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly developed antihyperglycemic medications. In addition to their glucose lowering properties, they have been shown to have favourable effects on the cardiovascular and renal outcome in patients with diabetes. one of the most interesting renal effects is reduction of proteinuria. The aim of our study was examine the effect of SGLT inhibitors on proteinuria in patients with glomerulonephritis. This study is a randomised controlled trial.

Clinical Trial Description

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly developed antihyperglycemic medications. In addition to their glucose lowering properties, they have been shown to have favourable effects on the cardiovascular and renal outcome in patients with diabetes.The favourable cardiovascular effects include increased diuresis , reduction of blood pressure and reduction of hospitalisation for heart failure one of the most interesting renal effects is reduction of proteinuria. The aim of our study was examine the effect of SGLT inhibitors on proteinuria in patients with glomerulonephritis. This study is a randomised controlled trial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05283057
Study type	Interventional
Source	Kasr El Aini Hospital
Contact
Status	Completed
Phase	Phase 3
Start date	February 20, 2020
Completion date	September 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03510286` - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Completed	`NCT05086549` - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Terminated	`NCT04051957` - Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury	Phase 2
Terminated	`NCT02057523` - Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients	Phase 4
Completed	`NCT02232763` - Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria	Phase 3
Completed	`NCT02226055` - An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka	N/A
Completed	`NCT00493727` - Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria	N/A
Active, not recruiting	`NCT00565396` - Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3	N/A
Recruiting	`NCT05759754` - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease	N/A
Withdrawn	`NCT02882373` - Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury	Phase 2
Completed	`NCT02327403` - Belatacept Conversion in Proteinuric Kidney Transplant Recipients	Phase 2
Recruiting	`NCT01773382` - The Effects of Weight Reduction in IgA Nephropathy	N/A
Completed	`NCT00915200` - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy	Phase 2
Completed	`NCT01029002` - The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease	Phase 3
Withdrawn	`NCT00541619` - Sympathetic Overactivity in Essential Hypertension	N/A
Withdrawn	`NCT00392132` - Impact of Screening Patients With HIV for Kidney Disease
Terminated	`NCT00001978` - Determination of Kidney Function
Recruiting	`NCT05457283` - A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria	Phase 3
Completed	`NCT04874753` - The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
Recruiting	`NCT02972346` - Availability Study of ACTH to Treat Children SRNS/SDNS	N/A